Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
Open Access
- 31 March 2020
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 9 (4), 155
- https://doi.org/10.3390/antibiotics9040155
Abstract
In the beginning of the 21st century, the frequency of antimicrobial resistance (AMR) has reached an apex, where even 4th and 5th generation antibiotics are becoming useless in clinical settings. In turn, patients are suffering from once-curable infections, with increases in morbidity and mortality. The root cause of many of these infections are the ESKAPEE pathogens (Enterococcus species, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli), which thrive in the nosocomial environment and are the bacterial species that have seen the largest rise in the acquisition of antibiotic resistance genes. While traditional small-molecule development still dominates the antibacterial landscape for solutions to AMR, some researchers are now turning to biological approaches as potential game changers. Monoclonal antibodies (mAbs)—more specifically, human monoclonal antibodies (Hu-mAbs)—have been highly pursued in the anti-cancer, autoimmune, and antiviral fields with many success stories, but antibody development for bacterial infection is still just scratching the surface. The untapped potential for Hu-mAbs to be used as a prophylactic or therapeutic treatment for bacterial infection is exciting, as these biologics do not have the same toxicity hurdles of small molecules, could have less resistance as they often target virulence proteins rather than proteins required for survival, and are narrow spectrum (targeting just one pathogenic species), therefore avoiding the disruption of the microbiome. This mini-review will highlight the current antibacterial mAbs approved for patient use, the success stories for mAb development, and new Hu-mAb products in the antibacterial pipeline.Keywords
This publication has 72 references indexed in Scilit:
- Direct Evaluation of Pseudomonas aeruginosa Biofilm Mediators in a Chronic Infection ModelInfection and Immunity, 2011
- Antibody Targeting the Ferritin-Like Protein ControlsListeriaInfectionInfection and Immunity, 2010
- Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoireProceedings of the National Academy of Sciences of the United States of America, 2009
- Assembly and Development of the Pseudomonas aeruginosa Biofilm MatrixPLoS Pathogens, 2009
- An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial ActivityInfection and Immunity, 2009
- Pivotal Involvement of Fcγ Receptor IIA in the Neutralization of Lipopolysaccharide Signaling via a Potent Novel Anti-TLR4 Monoclonal Antibody 15C1Published by Elsevier BV ,2007
- Human Monoclonal Antibody InhibitsPorphyromonas gingivalisHemagglutinin ActivityThe Journal of Periodontology, 2003
- Antibody-Based Therapies for Emerging Infectious DiseasesEmerging Infectious Diseases, 1996
- Production of Antibody to Tetanus Toxoid by Continuous Human Lymphoblastoid Cell LinesScience, 1978
- COMPARATIVE STATISTICS OF ANTITOXIN HORSES. A STUDY OF THE RECORDS OF ONE HUNDRED HORSES IMMUNIZED TO DIPHTHERIA TOXIN, WITH COMPOSITE OF CURVESThe Journal of Experimental Medicine, 1905